

Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the July 1, 2021 updates to the ADBL has been posted online at www.ab.bluecross.ca/dbl/publications.php.

Please refer to the July 1, 2021 updates for complete listings of products available by special authorization, restricted benefit, drug products with changes to criteria, drug products with changes to benefit status, added products, Least Cost Alternative (LCA) price changes, products with a price change and discontinued products.

Please note that the online Interactive Drug Benefit List (*iDBL*) at www.ab.bluecross.ca/dbl/idbl_main1.php is a near real-time application, and as such, contains the most up-to-date information.

Product supply shortages addressed for ADBL

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Cabergoline 0.5 mg Tablet (DIN 02455897) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **July 8, 2021**. The following grouping was removed from the Critical Supply Product List **June 8, 2021**.

CABERGOLINE

0.5 MG TABLET

00002455897	APO-CABERGOLINE	APX	\$ 12.3941
00002242471	DOSTINEX	PAL	\$ 15.6314

Removal of temporary benefits from the ADBL

Due to the shortage of Apo-Ibuprofen 400 mg Tablet (DIN 00506052) manufactured by Apotex Inc., Advil Extra Strength 400 mg Caplet (DIN 02244577), manufactured by Pfizer Consumer Healthcare, was added as a temporary benefit for the ADBL.

Apotex Inc. has advised Alberta Blue Cross that the shortage of Apo-Ibuprofen 400 mg Tablet (DIN 00506052) has been resolved.

As a result, Advil Extra Strength 400 mg Caplet (DIN 02244577) will no longer be considered a temporary benefit for the ADBL after **July 7, 2021**. The above grouping was removed from the Critical Supply Product List **June 8, 2021**.

continued next page

PHARMACY BENEFACT

continued from previous page

Due to the shortages of Mint-Spironolactone 100 mg Tablet (DIN 02488159) manufactured by Mint Pharmaceuticals Inc. and Teva-Spironolactone 100 mg Tablet (DIN 00613223) manufactured by Teva Canada Limited, Aldactone 100 mg Tablet (DIN 00285455), manufactured by Pfizer Canada ULC was added as a temporary benefit for the *ADBL*.

Teva Canada Limited has advised Alberta Blue Cross that the shortage Teva-Spironolactone 100 mg Tablet (DIN 00613223) has been resolved.

As a result, Aldactone 100 mg Tablet (DIN 0285455) will no longer be considered a temporary benefit for the *ADBL* after **July 9, 2021**. The above grouping was removed from the Critical Supply Product List **June 9, 2021**.

Due to the shortage of Tazorac 0.1% Topical Gel (DIN 02230785) manufactured by Allergan Inc., Tazorac 0.1% Topical Cream (DIN 02243895), manufactured by Allergan Inc. was added as a temporary benefit for the *ADBL*.

Allergan Inc. has advised Alberta Blue Cross that the shortage Tazorac 0.1% Topical Gel (DIN 02230785) has been resolved.

As a result, Tazorac 0.1% Topical Cream (DIN 02243895) will no longer be considered a temporary benefit for the *ADBL* after **July 23, 2021**. The above grouping was removed from the Critical Supply Product List **June 23, 2021**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

